Congratulations! You have access to the full report.
Download it now.

Download report

Already a Vizient Pharmacy Program member?
Access exclusive member insights

Not already enjoying membership benefits?
Learn how to access exclusive member insights


Projected drug price inflation rate
for July 1, 2022-June 30, 2023

Specialty drugs by therapeutic category
What our experts say

Purchases by therapeutic class

While oncology continues to be the highest therapeutic class by drug spend among Vizient members, DMARDs have the highest price change, given the pricing escalations anticipated for adalimumab and etanercept until effective biosimilar competition.

What our experts say

Proof that biosimilars make a difference

Utilization of biosimilar infliximab is decreasing the overall spend for this category of drugs despite the increase in overall utilization. Notice the market share percentage among Vizient members across the previous four quarters.

Percent Vizient Member Infliximab Biosimilar Market Share

Increase in outpatient service line utilization

Adalimumab crosses all three service lines with nine approved indications; but decrease in spend is expected as adalimumab biosimilars are brought to market in 2023.

  • 17% Dermatology
  • 15% Rheumatology
  • 11% Gastroenterology

Source: Vizient data

Diabetes management

Biosimilars now take the top position for diabetes drug spend, with the 2021 approval of interchangeable biosimilar, insulin glargine.

2.69% drug price inflation rate

Source: Vizient data

Let's end drug shortages together

Join the End Drug Shortages Alliance and be a part of the supply chain community driving transparency, quality, and access to additional production of essential medications.

Budget better with pharmacy analytics

Make strategic budgeting decisions, control spend, and ensure contract optimization with Vizient pharmacy analytics solutions.

Connect with our pharmacy experts. We are here to support you.